109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
整合多组学与功能验证揭示 ATP1B3 基因在肝细胞癌中对 TACE 治疗耐药的作用
Authors Zhang C, Hu Q, Meng H, Wu Q, Zeng L, Zheng L, Weng Q , Qiu R, Xu M, Chen M, Chen F , Zhao Z, Yang Y, Ji J
Received 1 May 2025
Accepted for publication 23 October 2025
Published 19 November 2025 Volume 2025:12 Pages 2565—2583
DOI https://doi.org/10.2147/JHC.S537990
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ahmed Kaseb
Cong Zhang,1,* Qin Hu,2,3,* Hui Meng,3 Qingqing Wu,3 Lulu Zeng,3 Liyun Zheng,1,3 Qiaoyou Weng,1,3 Rongfang Qiu,1,3 Min Xu,1,3 Minjiang Chen,1,3 Feng Chen,4 Zhongwei Zhao,1,3 Yang Yang,2,3,5 Jiansong Ji1– 3
1Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Lishui Hospital, School of Medicine, Zhejiang University, Lishui, 323000, People’s Republic of China; 2Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, 315300, People’s Republic of China; 3Department of Radiology, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, People’s Republic of China; 4Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 5Key Laboratory of Precision Medicine of Lishui, Lishui, 323000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiansong Ji, Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Lishui Hospital, School of Medicine, Zhejiang University, Lishui, 323000, People’s Republic of China, Email jijiansong@zju.edu.cn Yang Yang, Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, 315300, People’s Republic of China, Email yangyang0502@wmu.edu.cn
Background: Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but resistance to TACE is a major clinical challenge. This study aimed to identify genes associated with TACE refractoriness and their roles in HCC progression.
Methods: Gene expression profiles from 104 HCC patients treated with TACE were analyzed using unsupervised clustering to identify molecular subtypes. Key genes associated with TACE refractoriness were identified through univariate Cox regression and lasso, with ATP1B3 emerging as a candidate. Functional annotation of ATP1B3 was conducted using KEGG, GO, and GSEA analyses, while immune profiling and immunotherapy response were compared between ATP1B3-high and ATP1B3-low groups. Single-cell RNA sequencing (scRNA-seq) was employed to explore ATP1B3 expression and its cellular interactions. In vitro functional assays validated its role in migration, invasion, cell cycle, chemotherapy sensitivity, and apoptosis.
Results: Unsupervised clustering revealed two distinct molecular subtypes of HCC. Cluster 1 was associated with significantly prolonged overall and recurrence-free survival, whereas Cluster 2 exhibited aggressive tumor behavior and adverse clinical outcomes. ATP1B3 was identified as a pivotal gene linked to TACE refractoriness and poor prognosis. Elevated ATP1B3 expression was strongly correlated with metabolic dysregulation, heightened tumor aggressiveness, immune evasion, and diminished therapeutic responses to TACE, sorafenib, and immunotherapy. scRNA-seq analyses demonstrated widespread ATP1B3 expression across tumor and immune cell subsets, with ATP1B3-positive HCC cells displaying enhanced interactions with immune cells. Functional assays revealed that ATP1B3 overexpression promoted tumor migration, invasion, and chemoresistance, while its silencing induced cell cycle arrest, apoptosis, and increased sensitivity to cisplatin.
Conclusion: This study identifies TACE refractoriness-related gene ATP1B3 as a key regulator of tumor progression, immune evasion, and therapeutic resistance in HCC. These findings highlight ATP1B3 as a promising biomarker for patient stratification and a potential therapeutic target to improve clinical outcomes in HCC.
Keywords: hepatocellular carcinoma, TACE refractoriness, ATP1B3, transcriptomics, molecular subtypes
1Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Lishui Hospital, School of Medicine, Zhejiang University, Lishui, 323000, People’s Republic of China; 2Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, 315300, People’s Republic of China; 3Department of Radiology, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, People’s Republic of China; 4Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 5Key Laboratory of Precision Medicine of Lishui, Lishui, 323000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiansong Ji, Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Lishui Hospital, School of Medicine, Zhejiang University, Lishui, 323000, People’s Republic of China, Email jijiansong@zju.edu.cn Yang Yang, Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, 315300, People’s Republic of China, Email yangyang0502@wmu.edu.cn
Background: Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but resistance to TACE is a major clinical challenge. This study aimed to identify genes associated with TACE refractoriness and their roles in HCC progression.
Methods: Gene expression profiles from 104 HCC patients treated with TACE were analyzed using unsupervised clustering to identify molecular subtypes. Key genes associated with TACE refractoriness were identified through univariate Cox regression and lasso, with ATP1B3 emerging as a candidate. Functional annotation of ATP1B3 was conducted using KEGG, GO, and GSEA analyses, while immune profiling and immunotherapy response were compared between ATP1B3-high and ATP1B3-low groups. Single-cell RNA sequencing (scRNA-seq) was employed to explore ATP1B3 expression and its cellular interactions. In vitro functional assays validated its role in migration, invasion, cell cycle, chemotherapy sensitivity, and apoptosis.
Results: Unsupervised clustering revealed two distinct molecular subtypes of HCC. Cluster 1 was associated with significantly prolonged overall and recurrence-free survival, whereas Cluster 2 exhibited aggressive tumor behavior and adverse clinical outcomes. ATP1B3 was identified as a pivotal gene linked to TACE refractoriness and poor prognosis. Elevated ATP1B3 expression was strongly correlated with metabolic dysregulation, heightened tumor aggressiveness, immune evasion, and diminished therapeutic responses to TACE, sorafenib, and immunotherapy. scRNA-seq analyses demonstrated widespread ATP1B3 expression across tumor and immune cell subsets, with ATP1B3-positive HCC cells displaying enhanced interactions with immune cells. Functional assays revealed that ATP1B3 overexpression promoted tumor migration, invasion, and chemoresistance, while its silencing induced cell cycle arrest, apoptosis, and increased sensitivity to cisplatin.
Conclusion: This study identifies TACE refractoriness-related gene ATP1B3 as a key regulator of tumor progression, immune evasion, and therapeutic resistance in HCC. These findings highlight ATP1B3 as a promising biomarker for patient stratification and a potential therapeutic target to improve clinical outcomes in HCC.
Keywords: hepatocellular carcinoma, TACE refractoriness, ATP1B3, transcriptomics, molecular subtypes